Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.
After losing a fight over access to millions of seized documents, Fortescue has settled its trade secrets case against green iron company Element Zero.
A judge has declined to order US-based animal genomics company Scidera to file a position statement in its bovine gene patent infringement suit and said she was “running out of patience” after unsuccessful strike-out and summary dismissal applications by the defendants.
Andrew ‘Twiggy’ Forrest’s Fortescue can’t get access to nine million seized documents in its trade secrets spat against green iron start-up Element Zero.
Green iron startup Element Zero is challenging a bid by Fortescue for access to nine million seized documents in their trade secrets spat, saying its rival has not met the test for proving inadequate discovery of material.
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
A judge has expressed frustration over the fourth discovery fight this year in Fortescue’s trade secrets case against Element Zero, as the green iron startup claims its bigger rival is trying to drag out the litigation.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
The High Court has rejected Novartis’ plea that it overturn a ruling that found an extension of the term of the patent for its heart drug Entresto was invalidly granted.
Movie database giant IMDb has won a stoush with media company Zumedia, with IP Australia finding Zumedia’s ‘DMDb’ trade mark was likely to cause confusion.